TABLE 2.
Chemotherapy Combinations and Incidence of Infection and Febrile Neutropenia following that combination
| Chemotherapy Combination | Number of Cycles Administered | Incidence of Infection | Incidence of FN |
|---|---|---|---|
| Vincristine/Doxorubicin/Cyclophosphamide | 147 | 25.9% | 42.2% |
| Cisplatin/Etoposide | 87 | 20.7% | 33.3% |
| Ifosfamide/Etoposide | 66 | 15.2% | 9.1% |
| Carboplatin/Etoposide | 62 | 12.9% | 9.7% |
| Other | 4 | 25% | 25% |
Cisplatin/Etoposide: Cisplatin 40 mg/m2/day x 5 days, Etoposide 200 mg/m2 × 3 days
Vincristine/Doxorubicin/Cyclophosphamide: Vincristine 1.5 mg/m2 × 1 day, Doxorubicin 60 mg/m2 × 1 day, Cyclophosphamide 2000 mg/m2 × 2 days
Ifosfamide/Etoposide: Ifosfamide 1800 mg/m2 × 5 days, Etoposide 100 mg/m2 × 5 days
Carboplatin/Etoposide: Carboplatin 500 mg/m2 × 2 days, Etoposide 150 mg/m2 × 3 days